ID

37240

Description

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3; ODM derived from: https://clinicaltrials.gov/show/NCT02426658

Link

https://clinicaltrials.gov/show/NCT02426658

Keywords

Versions (2)
  1. 7/10/19 7/10/19 -
  2. 9/17/21 9/17/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 10, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Stage IV Non-Small Cell Lung Cancer NCT02426658

English

Eligibility Stage IV Non-Small Cell Lung Cancer NCT02426658

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have histologically confirmed stage iv non-squamous histology non-small cell lung cancer
Description

Non-Squamous Non-Small Cell Lung Carcinoma TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C4528750
UMLS CUI [1,2]
C3258246
ecog performance status of 3
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
sensitizing epidermal growth factor receptor (egfr), anaplastic lymphoma receptor tyrosine kinase (alk) and ros proto-oncogene 1, receptor tyrosine kinase (ros-1) mutations are either negative or unknown
Description

EGFR gene mutation Negative | ALK gene mutation Negative | ROS1 Gene Mutation Negative | EGFR gene mutation Unknown | ALK gene mutation Unknown | ROS1 Gene Mutation Unknown

Data type

boolean

Alias
UMLS CUI [1,1]
C3266992
UMLS CUI [1,2]
C1513916
UMLS CUI [2,1]
C2825843
UMLS CUI [2,2]
C1513916
UMLS CUI [3,1]
C4331213
UMLS CUI [3,2]
C1513916
UMLS CUI [4,1]
C3266992
UMLS CUI [4,2]
C0439673
UMLS CUI [5,1]
C2825843
UMLS CUI [5,2]
C0439673
UMLS CUI [6,1]
C4331213
UMLS CUI [6,2]
C0439673
absolute neutrophil count >= 1,500/mcl
Description

Absolute neutrophil count

Data type

boolean

Alias
UMLS CUI [1]
C0948762
platelets >= 100,000/mcl
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
creatinine clearance >= 45 ml/min
Description

Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1]
C0373595
women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Description

Childbearing Potential Contraceptive methods | Gender Contraceptive methods | Hormonal contraception | Contraception, Barrier | Sexual Abstinence

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
UMLS CUI [3]
C2985296
UMLS CUI [4]
C0004764
UMLS CUI [5]
C0036899
ability to understand and the willingness to sign an institutional review board (irb)-approved informed consent document
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
ability to understand and complete the european organization for research and treatment of cancer (eortc) quality of life (qol) instruments
Description

Comprehension EORTC - Quality of life questionnaire | Completion EORTC - Quality of life questionnaire

Data type

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C0451149
UMLS CUI [2,1]
C0205197
UMLS CUI [2,2]
C0451149
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have previously received chemotherapy for non-small cell lung cancer, or have received radiotherapy within 2 weeks prior to entering the study, or who have not recovered from adverse events due to treatment more than 2 weeks earlier
Description

Prior Chemotherapy Non-Small Cell Lung Carcinoma | Therapeutic radiology procedure | Adverse event Due to Therapeutic procedure | Recovery Lacking

Data type

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0007131
UMLS CUI [2]
C1522449
UMLS CUI [3,1]
C0877248
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0087111
UMLS CUI [4,1]
C2004454
UMLS CUI [4,2]
C0332268
patients whose tumors are positive for the sensitizing egfr mutation
Description

Neoplasms EGFR gene mutation Positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C3266992
UMLS CUI [1,3]
C1514241
patients whose tumors are positive for the sensitizing alk fusion
Description

Neoplasms ALK Fusion Protein positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C2825844
patients whose tumors are positive for the sensitizing ros-1 fusion
Description

Neoplasms ROS1 Fusion Positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C4331212
patients may not be receiving any other investigational agents
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
patients with symptomatic or recurrent brain metastases should be excluded from this clinical trial
Description

Metastatic malignant neoplasm to brain Symptomatic | Metastatic malignant neoplasm to brain Recurrent

Data type

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C2945760
history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed
Description

Allergic Reaction Compound Pemetrexed Similar

Data type

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C1706082
UMLS CUI [1,3]
C0210657
UMLS CUI [1,4]
C2348205
pregnant women are excluded from this study; breastfeeding should be discontinued
Description

Pregnancy | Breast Feeding To be stopped

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2,1]
C0006147
UMLS CUI [2,2]
C1272691
Back to the top of the page

Similar models

Eligibility Stage IV Non-Small Cell Lung Cancer NCT02426658

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Squamous Non-Small Cell Lung Carcinoma TNM clinical staging
Item
patients must have histologically confirmed stage iv non-squamous histology non-small cell lung cancer
boolean
C4528750 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
ECOG performance status
Item
ecog performance status of 3
boolean
C1520224 (UMLS CUI [1])
EGFR gene mutation Negative | ALK gene mutation Negative | ROS1 Gene Mutation Negative | EGFR gene mutation Unknown | ALK gene mutation Unknown | ROS1 Gene Mutation Unknown
Item
sensitizing epidermal growth factor receptor (egfr), anaplastic lymphoma receptor tyrosine kinase (alk) and ros proto-oncogene 1, receptor tyrosine kinase (ros-1) mutations are either negative or unknown
boolean
C3266992 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C2825843 (UMLS CUI [2,1])
C1513916 (UMLS CUI [2,2])
C4331213 (UMLS CUI [3,1])
C1513916 (UMLS CUI [3,2])
C3266992 (UMLS CUI [4,1])
C0439673 (UMLS CUI [4,2])
C2825843 (UMLS CUI [5,1])
C0439673 (UMLS CUI [5,2])
C4331213 (UMLS CUI [6,1])
C0439673 (UMLS CUI [6,2])
Absolute neutrophil count
Item
absolute neutrophil count >= 1,500/mcl
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets >= 100,000/mcl
boolean
C0032181 (UMLS CUI [1])
Creatinine clearance measurement
Item
creatinine clearance >= 45 ml/min
boolean
C0373595 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Gender Contraceptive methods | Hormonal contraception | Contraception, Barrier | Sexual Abstinence
Item
women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C2985296 (UMLS CUI [3])
C0004764 (UMLS CUI [4])
C0036899 (UMLS CUI [5])
Informed Consent
Item
ability to understand and the willingness to sign an institutional review board (irb)-approved informed consent document
boolean
C0021430 (UMLS CUI [1])
Comprehension EORTC - Quality of life questionnaire | Completion EORTC - Quality of life questionnaire
Item
ability to understand and complete the european organization for research and treatment of cancer (eortc) quality of life (qol) instruments
boolean
C0162340 (UMLS CUI [1,1])
C0451149 (UMLS CUI [1,2])
C0205197 (UMLS CUI [2,1])
C0451149 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Prior Chemotherapy Non-Small Cell Lung Carcinoma | Therapeutic radiology procedure | Adverse event Due to Therapeutic procedure | Recovery Lacking
Item
patients who have previously received chemotherapy for non-small cell lung cancer, or have received radiotherapy within 2 weeks prior to entering the study, or who have not recovered from adverse events due to treatment more than 2 weeks earlier
boolean
C1514457 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])
C0877248 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
C2004454 (UMLS CUI [4,1])
C0332268 (UMLS CUI [4,2])
Neoplasms EGFR gene mutation Positive
Item
patients whose tumors are positive for the sensitizing egfr mutation
boolean
C0027651 (UMLS CUI [1,1])
C3266992 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
Neoplasms ALK Fusion Protein positive
Item
patients whose tumors are positive for the sensitizing alk fusion
boolean
C0027651 (UMLS CUI [1,1])
C2825844 (UMLS CUI [1,2])
Neoplasms ROS1 Fusion Positive
Item
patients whose tumors are positive for the sensitizing ros-1 fusion
boolean
C0027651 (UMLS CUI [1,1])
C4331212 (UMLS CUI [1,2])
Investigational New Drugs
Item
patients may not be receiving any other investigational agents
boolean
C0013230 (UMLS CUI [1])
Metastatic malignant neoplasm to brain Symptomatic | Metastatic malignant neoplasm to brain Recurrent
Item
patients with symptomatic or recurrent brain metastases should be excluded from this clinical trial
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C2945760 (UMLS CUI [2,2])
Allergic Reaction Compound Pemetrexed Similar
Item
history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed
boolean
C1527304 (UMLS CUI [1,1])
C1706082 (UMLS CUI [1,2])
C0210657 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
Pregnancy | Breast Feeding To be stopped
Item
pregnant women are excluded from this study; breastfeeding should be discontinued
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial